Wondering about that new position in your portfolio? For some Abbott Labs shareholders, the new year brought with it a new company called AbbVie. Formerly Abbott's branded pharmaceuticals business, shares of the new stock were distributed to investors on Jan. 2. In the following video, Brenton and Max discuss the key issues that new AbbVie shareholders have to understand.
To help investors better understand the Abbott-AbbVie situation, The Fool has created a brand new premium report on both stocks. Inside, we outline all of the must-know opportunities and risks facing the companies, so make sure to claim this 2-for-1 report by clicking here now.
The article AbbVie: Pharma's New Kid on the Block originally appeared on Fool.com.
Brenton Flynn, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.